Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• K-RAS mutations are common drivers in human cancers.
• Targeting oncogenic K-RAS mutants remains a significant therapeutic challenge.
• NEDD4-1 is an E3 ubiquitin ligase for wild-type RAS proteins.

Purpose of the Study:

• To develop a novel strategy for targeting and degrading oncogenic K-RAS mutants.
• To identify a compound that can specifically inhibit K-RAS mutant-driven cancer progression.

Main Methods:

• Development of a bifunctional compound, XMU-MP-9.
• Investigating the compound's mechanism of action on NEDD4-1 and K-RAS interaction.
• Assessing the compound's effect on K-RAS mutant ubiquitination, degradation, and cancer cell proliferation.

Main Results:

• XMU-MP-9 promotes ubiquitination and degradation of various K-RAS mutants (e.g., K-RAS^G12V).
• The compound inhibits proliferation and tumor development in K-RAS mutant cancer cells.
• XMU-MP-9 binds NEDD4-1 and K-RAS, enhancing their interaction and leading to K-RAS ubiquitination at K128.

Conclusions:

• XMU-MP-9 offers a novel therapeutic strategy by degrading oncogenic K-RAS mutants.
• This approach effectively inhibits K-RAS mutant-driven tumor development.
• Targeting K-RAS degradation presents a promising avenue for cancer therapy.